Treats hypertension. ANDA 216304, held by Utopic Pharms. Diltiazem Hydrochloride.
As of Nov 16, 2026, ANDA 216304 (Diltiazem Hydrochloride), held by Utopic Pharms, was first approved by FDA on Aug 8, 2022, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Diltiazem Hydrochloride Extended-Release Capsules are indicated for the treatment of hypertension. Diltiazem hydrochloride may be used alone or in combination with other antihypertensive medications, such as diuretics. Diltiazem Hydrochloride Extended-Release Capsules are indicated for the management of chronic stable angina.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 8, 2022 | Original application | Approved | None posted |
| Diltiazem Hydrochloride120MG · capsule, extended release;oral | Diltiazem Hydrochloride | Rx |
| Diltiazem Hydrochloride180MG · capsule, extended release;oral | Diltiazem Hydrochloride | Rx |
| Diltiazem Hydrochloride240MG · capsule, extended release;oral | Diltiazem Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters